Cardiff Oncology Q3: Cash Falls to $33.8M, Going Concern Reiterated as Phase 3 Looms
CRDF is trading near its 52-week low of $0.72 (1.0% above the low).
Summary
Cardiff's Q3 10-Q shows $33.8 million in cash and investments — enough to fund operations only to the end of Q3 2027 — with management repeating substantial doubt about going concern ahead of a Phase 3 mCRC trial.
Key Events · Earnings and Guidance · CRDF
-
Going Concern Doubt Reiterated
Management concluded there is substantial doubt about the company's ability to continue as a going concern; $33.8 million in cash, cash equivalents and short-term investments is not sufficient to meet funding requirements for at least the next 12 months.
-
Cash Burn Leaves Runway to Q3 2027
Cash and investments fell to $33.8 million at September 30, 2026 from $58.3 million at December 31, 2025, with $33.9 million of operating cash used in the nine months.
-
Loss Narrows on Lower R&D
Nine-month net loss was $30.4 million versus $38.6 million a year earlier; R&D fell to $17.7 million from $30.3 million as trials completed, while SG&A rose to $14.3 million from $11.2 million on NMS litigation costs.
-
July Offering Adds $9.1M Net
The July 2026 registered direct sold 9,293,079 shares with warrants at $1.05 ($1.455 for insiders) for $10.05 million gross and $9.1 million net; 9,757,732 warrants at a $1.31 strike become exercisable January 19, 2027.
Analysis · CRDF · Life Sciences
Cardiff ended September with $33.8 million in cash and investments, down from $58.3 million at year-end, and management says that only funds operations to the end of Q3 2027 — not enough for the next 12 months. That is a substantial-doubt going-concern statement on a company that must fund a ~640-patient Phase 3 mCRC trial, so another raise is close to certain and dilution is the base case. The offset is that spending is coming down (R&D $17.7 million for nine months vs $30.3 million) and the net loss narrowed to $30.4 million from $38.6 million, while the July offering brought in $9.1 million net and the Nerviano dispute is settled. The stock trades near its 52-week low of $0.72, which makes the next financing expensive.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRDF was trading at $0.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $56.6M. The 52-week trading range was $0.72 to $3.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.